159634-47-6|Ibutamoren|(R)-2-amino-N-(3-(benzyloxy)-1-(1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl)-1-oxopropan-2-yl)-2-methylpropanamide|-范德生物科技公司

Ibutamoren

NMR下载 COA and HPLC MSDS下载
names：
(R)-2-amino-N-(3-(benzyloxy)-1-(1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl)-1-oxopropan-2-yl)-2-methylpropanamide
CAS号：
159634-47-6
MDL Number：
MF(分子式)： C27H36N4O5S MW(分子量)： 528.66
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Ibutamoren
英文别名	Ibutamoren; L 163191; L-163191; L163191; MK-677; MK 677; MK677;
CAS号	159634-47-6
Inchi	InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1
InchiKey	UMUPQWIGCOZEOY-JOCHJYFZSA-N
分子式 Formula	C27H36N4O5S
分子量 Molecular Weight	528.66
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Ibutamoren(CAS:159634-47-6 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Ibutamoren, also known as MK-677 (L-163,191), is a drug which acts as a potent, orally active growth hormone secretagogue, mimicking the GH stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels.It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. It also alters metabolism of body fat and so may have application in the treatment of obesity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017 Nov 28;318(20):2004-2010. doi: 10.1001/jama.2017.17069. Erratum in: JAMA. 2018 Feb 20;319(7):724. PubMed PMID: 29183075; PubMed Central PMCID: PMC5820696.

[2]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. Review. PubMed PMID: 28400207; PubMed Central PMCID: PMC5632578.

[3] Harmatz ES, Stone L, Lim SH, Lee G, McGrath A, Gisabella B, Peng X, Kosoy E, Yao J, Liu E, Machado NJ, Weiner VS, Slocum W, Cunha RA, Goosens KA. Central Ghrelin Resistance Permits the Overconsolidation of Fear Memory. Biol Psychiatry. 2017 Jun 15;81(12):1003-1013. doi: 10.1016/j.biopsych.2016.11.009. Epub 2016 Nov 29. PubMed PMID: 28010876; PubMed Central PMCID: PMC5447505.

[4] Patel K, Joharapurkar A, Dhanesha N, Patel V, Kshirsagar S, Raval P, Raval S, Jain MR. Thyroid hormone modulates food intake and glycemia via ghrelin secretion in Zucker fatty rats. Drug Res (Stuttg). 2014 Oct;64(10):523-9. doi: 10.1055/s-0033-1363222. Epub 2013 Dec 19. PubMed PMID: 24357139.

[5] Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. doi: 10.1111/jphp.12010. Epub 2012 Nov 27. PubMed PMID: 23488781.

6: Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9. PubMed PMID: 21067829.7: Ceda GP, Dall'Aglio E, Morganti S, Denti L, Maggio M, Lauretani F, Andrea A, Ceresini G, Cattabiani C, Valenti G. Update on new therapeutic options for the somatopause. Acta Biomed. 2010;81 Suppl 1:67-72. Review. PubMed PMID: 20518193.8: Hakim RM, Ikizler TA. Anabolic interventions in ESRD: light at the end of the tunnel? Am J Kidney Dis. 2009 Aug;54(2):201-4. doi: 10.1053/j.ajkd.2009.04.018. Epub 2009 Jun 25. PubMed PMID: 19556045.9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46. PubMed PMID: 19455266.10: Webster J. Rejuvenation in older adults receiving oral ghrelin. Ann Intern Med. 2009 May 5;150(9):654-5; author reply 655. PubMed PMID: 19414853.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开